No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers

Abstract

There are no clinically significant pharmacokinetic interactions between lenalidomide and substrates or inhibitors of P-gp.